Despite numerous guidelines on the management of anaemia in surgical patients, there is no pragmatic guidance for the diagnosis and management of anaemia and iron deficiency in the postoperative period. A number of experienced researchers and clinicians took part in a two-day expert workshop and developed the following consensus statement. After presentation of our own research data and local policies and procedures, appropriate relevant literature was reviewed and discussed. We developed a series of bestpractice and evidence-based statements to advise on patient care with respect to anaemia and iron deficiency in the postoperative period. These statements include: a diagnostic approach to iron deficiency and anaemia in surgical patients; identification of patients appropriate for treatment; and advice on practical management and follow-up that is easy to implement. Available data allow the fulfilment of the requirements of Pillar 1 of Patient Blood Management. We urge national and international research funding bodies to take note of these recommendations, particularly in terms of funding large-scale prospective, randomised clinical trials that can most effectively address the important clinical questions and this clearly unmet medical need.
Recommendations for best clinical practice
• All patients who have undergone major surgery (defined as blood loss > 500 ml or lasting > 2 h) and who had pre-operative anaemia or moderate-to-severe blood loss during surgery must be screened for anaemia after surgery.
• During recovery from uncomplicated major surgery, haemoglobin concentrations should be monitored, either by standard laboratory or point-of-care testing, on a regular daily basis, at least until the third postoperative day, to detect anaemia (haemoglobin < 130 g.l À1 for men, < 120 g.l À1 for women).
• Postoperatively, iron deficiency should be defined by ferritin concentration < 100 lg.l
À1
, ferritin < 100-300 lg.l À1 and transferrin saturation < 20%, or reticulocyte haemoglobin content < 28 pg. High blood loss during surgery may also indicate the need for iron replacement in anaemic patients.
• In the postoperative period, when the administration of iron is necessary, early intravenous (i.v.) iron therapy is recommended, after considering contraindications.
Where possible, it should be administered using a single high-dose preparation for the repletion of iron stores.
• For non-cancer patients with severe postoperative anaemia and inflammation-induced blunted erythropoiesis, or those declining blood transfusion, we suggest considering additional treatment with an erythropoiesis-stimulating agent.
• If patient blood management measures did not prevent the development of severe postoperative anaemia, the adoption of a restrictive transfusion threshold (haemoglobin level: 70-80 g.l
, depending on patient comorbidities) is recommended in most adult, clinically stable hospitalised patients.
• We recommend establishing a patient blood management expert group in every hospital.
Why was this consensus statement developed?
The concept 'patient blood management' (PBM) is defined as "the timely application of evidence-based medical and surgical concepts designed to manage anaemia, optimise haemostasis and minimise blood loss in order to improve patient outcomes after surgery"' [1] .
Patient blood management has been shown to reduce transfusion, healthcare costs and morbidity and mortality [2] . Treatment of pre-operative anaemia and isolated iron deficiency are crucial measures for PBM [3, 4] . However, detection and early treatment of pre-operative anaemia and iron deficiency is an accepted logistical challenge and, as a consequence, some patients may undergo surgery without the chance to address their anaemia [3] .
In addition, there has been increased emphasis on accelerated discharge after surgery and the use of restrictive transfusion thresholds in order to improve outcomes and reduce transfusion requirements, which may have led to overlooking potential opportunities to optimise anaemic patients and improve their functional recovery [5, 6] .
Therefore, an additional focus on the early detection and treatment of postoperative iron deficiency and anaemia is a novel and complementary measure within the concept of PBM; this allows the attending physician to target patients who lost significant red cell mass during surgery and may require specific attention postoperatively or following discharge [7] .
How does this consensus statement differ from other available statements and/or guidelines?
There are a number of statements and guidelines from professional associations recommending a systematic approach to this problem for the management of pre-operative anaemia [1, [7] [8] [9] [10] [11] [12] [13] [14] [15] . Most of these guidelines also recommend the use of a restrictive transfusion threshold for treating acute postoperative anaemia, but recommendations for pharmacological management of anaemia are scarce, or even absent [1, [7] [8] [9] [10] [11] [12] [13] [14] [15] . We aimed to update and utilise these few current recommendations to provide a working practice document, based on scientific evidence and the clinical experience of an expert panel, on 'how to' feasibly introduce these postoperative anaemia guidelines into clinical practice. Our goal was to provide pragmatic, clear and easy-to-follow clinical guidance for the diagnosis and treatment of postoperative anaemia and iron deficiency in order to improve patient recovery, reduce the need for blood transfusion and improve functional outcomes in a cost effective manner.
Our recommendations are intended for non-actively bleeding adult patients in whom all the principles of PBM have been implemented pre-and intra-operatively for the prevention of postoperative iron deficiency and anaemia.
Definition, prevalence and pathophysiology of postoperative anaemia
Postoperative anaemia may be present in up to 80-90% of patients undergoing major surgery, although this prevalence varies widely according to different definitions [16, 17] . Anaemia is defined by the World Health Organization (WHO) as a haemoglobin concentration < 130 g.l À1 for men, < 120 g.l À1 for non-pregnant women and < 110 g.l
À1
for pregnant women [18] . Although debated [19] , and since these definitions are widely accepted, they may be applied ) [18] .
Although multifactorial in origin, pre-operative anaemia, peri-operative blood loss (surgical bleeding, coagulopathy, phlebotomies, etc) and postoperative blunted erythropoiesis are the main contributing factors to postoperative anaemia after major surgery. Haemodilution due to excessive fluid administration, which may cause 'dilutional' anaemia or aggravate pre-existing anaemia, and other nutritional deficiencies (e.g. vitamin B 12 , folic acid) and pharmacological interactions are also contributing factors [20] .
Low pre-operative haemoglobin, female sex and smaller body surface area have been identified as risk factors for the development of postoperative anaemia and increased transfusion needs [21] . Additionally, in the general population, the prevalence of anaemia increases with age; older persons are more likely to undergo major surgery and to present with comorbidities, thus increasing the risk of postoperative anaemia, and reducing its tolerability [22, 23] .
The end of the surgical procedure does not always [20] . However, the use of restrictive transfusion thresholds, as emphasised in the third pillar of PBM, also contributes to a higher prevalence of moderate-to-severe anaemia on discharge from hospital (haemoglobin concentration < 100 g.l
), unless proactive measures are implemented [20] .
Anaemia in the postoperative period, as well as in critical illness, may be aggravated by reduced erythropoietin production and secretion due to inflammatory mediators; blunted bone marrow response to erythropoietin; and decreased iron availability due to down-regulation of intestinal absorption and impaired mobilisation of iron from body stores [24, 25] . Inflammatory cytokines stimulate the secretion of hepcidin, a hormone that targets ferroportin, the only known cellular exporter of iron. This induces the internalisation and degradation of ferroportin, thereby largely inhibiting intestinal iron absorption and greatly reducing iron release from body stores (iron sequestration) [26] .
What are the unmet medical needs of postoperative anaemia?
The concerns surrounding postoperative anaemia relate to its potential impact on recovery, rehabilitation, hospital re-admission or re-operation, and patient well-being.
Reducing allogeneic blood transfusion improves long-term outcome and survival [27] . However, restrictive transfusion protocols have led to patients being discharged with lower haemoglobin levels than before. With the current paucity of data, it remains unclear whether a lower discharge haemoglobin level may allow optimal functional recovery and quality of life [28] [29] [30] [31] [32] [33] [34] . There has been limited research on the consequences of postoperative anaemia in the recovery phase from surgery, with only a small number of studies after cardiac and hip and knee surgery, which demonstrated the association between postoperative anaemia and adverse outcomes such as prolonged recovery, increased mortality and likelihood of re-admission [31] [32] [33] . Postoperative anaemia may also potentially be associated with early postoperative myocardial infarction [34] . Correction of postoperative anaemia, as suggested in this consensus statement, is intended to prevent such side-effects, but studies are urgently needed to prove this. for dynamic changes over time may permit detection of occult bleeding and response to therapy [36] .
Diagnosis of postoperative anaemia

What are the confounding factors?
In the setting of postoperative care, a number of confounding factors may impact on accurate haemoglobin measurement. Volume overload and haemodilution after major surgery are potential causes for low haemoglobin levels, despite normal and stable red cell mass. Therefore, the diagnosis of anaemia based on simple haemoglobin concentration may be misleading, and is confounded by plasma volume derangements, resulting in significant overdiagnosis [37] . Potential volume overload should be taken into account, and may improve after diuresis. , or reticulocyte haemoglobin content < 28 pg. These values and parameters may signal the need for intervention in anaemic patients [38] [39] [40] [41] .
When should postoperative anaemia be treated? Red cell transfusion should be restricted to patients with severe anaemia (haemoglobin < 70-80 g.l
À1
) and clinical signs and symptoms [7, [10] [11] [12] [47] [48] [49] . Red cell transfusion should be considered in patients with active bleeding and in those severely anaemic once bleeding has been stopped [7, [10] [11] [12] [47] [48] [49] . However, more research is required on specific transfusion thresholds in specific high-risk patients. (Table 1 ) [40, 64] .
What are the true risks and contraindications of i.v.
iron?
Many clinicians and health authorities still consider that i.v. iron is strongly associated with major side-effects such as anaphylaxis, infection or oxidative stress.
However, these side-effects appear not to be significant with the newer i.v. iron preparations, such as ferric carboxymaltose, iron isomaltoside and low molecular weight iron dextran [64] [65] [66] .
After an extensive review of the data, the European with serious hypersensitivity to other parenteral iron products; or in the first trimester of pregnancy [67] .
Elemental iron is an essential growth factor for bacteria, with many species expressing iron transport proteins that compete with transferrin, and it has long been suggested that patients with iron overload are at increased risk of infection [72] . However, data from metaanalyses and large observational studies showed that peri-operative i.v. iron did not increase postoperative infection or 30-day mortality rates in surgical patients [64, 66] . In contrast, red cell transfusion delivers haem and labile iron which readily supports bacterial growth [73] .
Nevertheless, in the absence of definitive clinical data, it would seem logical to refrain from i.v. iron administration in the setting of acute infection [8] .
The available evidence relating i.v. iron administration to oxidative stress leading to atherogenesis and vascular remodelling, is sparse and indirect. It is mostly derived from retrospective observational studies addressing long-term i.v. iron therapy [70] , whereas in the postoperative period, very short-term i.v. iron courses are administered (one or two large doses) [64] . Thus, it does not seem to be of concern in the postoperative setting.
Should we treat iron deficiency without anaemia?
A normal haemoglobin level does not exclude iron deficiency. In fact, the WHO recognises that 'mild' anaemia (haemoglobin 110-119/129 g.l
À1
) is a misnomer, as iron deficiency is already advanced by the time anaemia is detected, and has consequences even when anaemia is not clinically apparent [18] .
Non-anaemic patients with reduced or absent iron stores may have symptoms such as fatigue or reduced exercise tolerance, as iron is required for optimal mitochondrial function, and is essential for respiration and energy production [40, 74] . Current guidelines do not recommend routine iron screening in the absence of anaemia. However, the benefits of oral or i.v. iron replacement for non-anaemic iron deficiency-associated fatigue have been demonstrated in menstruating women, runners and blood donors [75] [76] [77] [78] .
In congestive heart failure, a frequent comorbidity among surgical patients, non-anaemic iron deficiency was independently associated with compromised physical performance and quality of life, and an increase in all-cause and cardiovascular mortality; treatment of non-anaemic iron deficiency with i.v. iron may improve functional status within four weeks, and reduces hospitalisations for cardiovascular reasons and mortality [79, 80] .
In addition, improvements are maintained after 24 and 52 weeks [79] [80] [81] .
In observational studies of patients undergoing abdominal or cardiac surgery, pre-operative non-anaemic iron deficiency was associated with poor outcomes, including: increased rates of postoperative infection; transfusion; fatigue; and prolonged hospital stay [82] [83] [84] .
Although it is presently unknown whether pre-operative correction of non-anaemic iron deficiency may offset the excess of risk of postoperative complications, some guidelines recommend peri-operative iron supplementation for patients with non-anaemic iron deficiency [14, 85] .
Secondary thrombocytosis can also be seen after Is there a role for erythropoiesisstimulating agents?
In patients without a previous indication, postoperative administration of rHuEPO is an off-label use of this medicinal product. The effects of postoperative rHuEPO have been evaluated in case series, mostly in Jehova's Witnesses and in two RCTs, yielding inconclusive results due to selection bias [58] or premature interruption [59] .
In women with moderate-to-severe postpartum anaemia, five RCTs evaluated the effects of iron sucrose (300-1600 mg) or iron sucrose plus rHuEPO (20,000-40,000 IU) on haemoglobin recovery and transfusion needs [15] . A trend to faster haemoglobin increment was observed with rHuEPO plus i.v. iron compared with i.v. iron alone, but no significant differences in transfusion rates which were very low, were observed. The benefits seemed to be greatest in the rHuEPO-treated sub-group with elevated C-reactive protein levels after Caesarean section [15] .
Although it does not strictly refer to surgical patients, a recent meta-analysis also found a reduction in mortality rates (risk ratio (RR) 0.63, 95%CI 0.49-0.79, p < 0.0001) in critically ill trauma patients who received rHuEPO (nine studies, 2607 patients), without increasing the risk of thromboembolic complications [90] . In cardiac surgery patients, rHuEPO seems to exert neurological and renal protective effect [91, 92] . The mechanisms underlying these non-erythropoietic effects of rHuEPO need to be elucidated before recommending its use in patients without an approved indication.
Short-term pre-operative (1-4 days before operation) administration of rHuEPO to anaemic patients, with or without i.v. iron, has been shown to reduce postoperative transfusion in elective orthopaedic and cardiac surgery [93, 94] . In hip fracture repair surgery, there are conflicting data. One RCT failed to show a reduction in red cell transfusion in patients receiving rHuEPO plus i.v. iron [95] . However, they included patients with haemoglobin < 100 g.l
but did not study women with haemoglobin ≥ 120 g.l Red blood cell transfusion: transfusion thresholds for whom and when?
Allogeneic red cell transfusion is associated with a significant increase in peri-operative morbidity and mortality [2, [98] [99] [100] . In addition, there is a worldwide shortage of blood, with substantial associated costs to the manufacturer and health systems [101] . Moreover, red cell transfusion risks infectious, immunological, haemolytic, nonhaemolytic adverse reactions, cardiac and pulmonary complications [2, 98] . Despite successful implementation of PBM programmes, red cell transfusion is still widely used as a default treatment for the majority of patients with acute postoperative anaemia [102] .
Historically, the standard for red cell transfusion was a liberal transfusion threshold, namely haemoglobin level < 100 g.l À1 (or haematocrit < 30%). This arbitrary transfusion threshold has been gradually lowered towards haemoglobin 70-80 g.l
, according to data derived from a number of RCTs evaluating the effect on patient outcomes of restrictive vs. more liberal red cell transfusion strategies in a variety of clinical settings. When subjected to pooled analysis in several systematic reviews and meta-analyses (Supporting Information online, Appendix S2) [103] [104] [105] [106] [107] [108] , data from these RCTs show that, in terms of morbidity and mortality, a restrictive red cell transfusion strategy is equivalent to or more beneficial than a liberal strategy [101, 109] .
In addition, evidence-based guidelines have translated the results of RCTs and meta-analyses into clinical practice [7, [10] [11] [12] [47] [48] [49] [7, 10-12, 47-49, 112] . Confounding factors on haemoglobin levels have to be considered, as discussed above.
Cost assessment implications
There suggests that cost analysis of this intervention is not meaningful [51] [52] [53] [54] [55] [56] [57] .
Suggestions for further research
During the writing of this consensus statement, it became apparent that there are areas of postoperative anaemia management for which further research is required:
• Monitoring. It is really important to emphasise the need for detailed anaemia studies following discharge with periodic monitoring of haemoglobin and iron parameters in relation to functional recovery.
• • Patients. It is also necessary to define which patient groups are most likely to benefit from such treatments.
• Mechanisms of action. The mechanisms underlying non-erythropoietic effects of rHuEPO, such as neurological and renal protective effects, and iron need to be elucidated.
• 
